World Data from an Observational Study

Objective

Ranolazine, a late sodium current inhibitor, is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antiischaemic therapies. Нis study was conducted to assess the use of ranolazine as well as its safety and eٹcac\ in patients with stable angina pectoris from diوٴerent causes in a real world scenario.

Methods

Patients with stable angina pectoris (AP) receiving ranolazine were enrolled in this non-interventional study. Data were documented at baseline and aіer 3 months of ranolazine treatment. Endpoints included changes in the number of AP attacks per week, frequency of using short-acting nitrates, current status of the CCS classification, overall estimate of quality of life assessed by both, the physician and the patient, and safety.

Results

 In total, 1,537 patients were eligible for eٹcac\ evaluation. $іer 3 months, the mean (±SD) number of AP episodes per week significantl\ decreased from 4.4 ± 4.0 at baseline to 1.1 ± 1.8 (p<0.0001), and the weekly use of short-acting nitrates was significantl\ reduced from 3.4 ± 3.4 to 0.8 ± 1.5 (p<0.0001). Improvement occurred independent of diagnosed coronary heart disease (CHD). Нe CCS classification improved in 69.0% of patients and remained stable in 27.1%. Quality of life, assessed on a numerical analogue scale by physicians and patients, improved significantl\ by 43.7% and 44.9%, respectively (p<0.0001). Safety analysis was based on 2,726 patients. A total of 63 adverse drug reactions (ADRs) occurred in 37 patients (1.4%) and led to discontinuation in 34 patients (1.2%). By the end of the observation period, all ADRs were resolved or resolving.

Conclusion

Нe adjuvant therapy with ranolazine is an eوٴective treatment option with a positive benefit-risk balance for patients with angina pectoris of diوٴerent causes, e.g. small vessel disease, endothelial dysfunction, including those without prior CHD diagnosis.

Published Date: 2025-06-27 | Received Date: 2025-06-01